Lataa...
Elimination of a cholecystokinin receptor agonist “trigger” in an effort to develop positive allosteric modulators without intrinsic agonist activity
Cholecystokinin (CCK) acts at the type 1 cholecystokinin receptor (CCK1R) to elicit satiety and is a well-established drug target for obesity. To date, small molecule agonists have been developed, but have failed to demonstrate adequate efficacy in clinical trials, and concerns about side effects an...
Tallennettuna:
| Julkaisussa: | Bioorg Med Chem Lett |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4408270/ https://ncbi.nlm.nih.gov/pubmed/25862198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2015.03.051 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|